Codexis Appoints David Butler, PhD, to Strategic Advisory Board Read more »

Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen®… Read more »

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on… Read more »

Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company… Read more »

The Company remains on track to submit its 510(k) package in calendar H2 2026, working toward planned entry into the… Read more »

Veteran U.S.-based CMC, supply chain, and quality leaders join Achieve as the Company continues the transition of cytisinicline finished product… Read more »

CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion Read more »

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical… Read more »

Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech… Read more »

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha),… Read more »

MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the… Read more »

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced… Read more »

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes  Read more »

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the… Read more »

Company to hold a conference call at 8:30 a.m. ET Company to hold a conference call at 8:30 a.m. ET Read more »

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field… Read more »

$8B Curium-Lantheus deal creates a global radiopharmaceutical leader, expanding reach across oncology, neurology and cardiology in 70+ countries. Read more »

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk… Read more »

CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to… Read more »

WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology… Read more »

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev Dr. Mehmud’s appointment further aligns the… Read more »

PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical… Read more »

Kraig Labs (OTCQB: KBLB) is featured in a new Veritasium episode that includes Kraig’s spider silk operations and testing the… Read more »

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 Read more »

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Read more »

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Read more »

Ocular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA… Read more »

First-in-class pan-RAS(ON) ADC is cleared for clinical development Read more »

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease Read more »

                             Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory… Read more »

Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the… Read more »

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative… Read more »

ROCKVILLE, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and… Read more »

•   Q2’26 Total Net Revenue of $343 Million, Up 14% YoY Read more »

ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc.… Read more »

Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its… Read more »

MELBOURNE, Australia and OXFORD, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) — Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying… Read more »

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”),… Read more »

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”),… Read more »

NANJING, China, Aug. 02, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code:… Read more »

They appointed a New CCO and CBO to highlight their commitment to US commercialization Read more »

Toronto, Canada, Aug. 02, 2026 (GLOBE NEWSWIRE) — NOX Peptides has released updated quality assurance and testing information for the… Read more »

BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies,… Read more »

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines… Read more »

CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX… Read more »

TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in… Read more »

Basel, July 31, 2026 – Novartis today announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide… Read more »

Press Release Paris, 31 July 2026 Read more »

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing… Read more »

Partnership establishes the framework for the first regulated psychedelic therapy program in the Commonwealth, uniting Rose Hill’s pharmaceutical-grade Psychedelic Therapeutic… Read more »